Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B‐cell lymphoma not eligible for autologous stem cell transplantation

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 5, 2015-03 ,pp. : 663-670

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab in Combination with Interferon-Alpha in Relapsed and Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma

By  

Acta Haematologica, Vol. 106, Iss. 3, 2001-11 ,pp. : 141-142

Karger

Access to resources Recommend Favorite

A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B‐cell non‐Hodgkin lymphoma: ECOG3402

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 5, 2015-09 ,pp. : 679-686

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 6, 2015-03 ,pp. : 811-819

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients

By  

Acta Haematologica, Vol. 136, Iss. 2, 2016-05 ,pp. : 76-84

Karger

Access to resources Recommend Favorite